American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F20%3A00079426" target="_blank" >RIV/00023001:_____/20:00079426 - isvavai.cz</a>

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S1053249820313462?token=D8C576C0FFCB122168ACF3B4008D62D671B468C5B30CF7402E738B2C1FE1D5EE9ADBE4C8495BFEAA93B59E0667B79DE3" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1053249820313462?token=D8C576C0FFCB122168ACF3B4008D62D671B468C5B30CF7402E738B2C1FE1D5EE9ADBE4C8495BFEAA93B59E0667B79DE3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.healun.2020.01.1329" target="_blank" >10.1016/j.healun.2020.01.1329</a>

Jazyk výsledku

angličtina

Název v původním jazyce

American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support

Popis výsledku v původním jazyce

Mechanical circulatory support (MCS) evolved from an engineering dream to clinical reality during the 1980s when increasing numbers of patients were dying on heart transplant wait lists. Following the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Trial, the US Food and Drug Administration (FDA) approved a pulsatile implantable left ventricular assist device (LVAD) for long-term implantation in 2002. When the FDA approved the first US continuous flow (CF) LVAD in 2008, the landscape had changed dramatically. With demonstrated survival on device exceeding 80% at 1 year, implants in the United States progressively increased to nearly 3000 per year. With the maturation of this field, guidelines for patient care and decision making have become more evidenced-based. This consensus guidelines document focuses on selected topics in patient management.

Název v anglickém jazyce

American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support

Popis výsledku anglicky

Mechanical circulatory support (MCS) evolved from an engineering dream to clinical reality during the 1980s when increasing numbers of patients were dying on heart transplant wait lists. Following the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Trial, the US Food and Drug Administration (FDA) approved a pulsatile implantable left ventricular assist device (LVAD) for long-term implantation in 2002. When the FDA approved the first US continuous flow (CF) LVAD in 2008, the landscape had changed dramatically. With demonstrated survival on device exceeding 80% at 1 year, implants in the United States progressively increased to nearly 3000 per year. With the maturation of this field, guidelines for patient care and decision making have become more evidenced-based. This consensus guidelines document focuses on selected topics in patient management.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of heart and lung transplantation

ISSN

1053-2498

e-ISSN

—

Svazek periodika

39

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

33

Strana od-do

187-219

Kód UT WoS článku

000514215800001

EID výsledku v databázi Scopus

2-s2.0-85079365178